Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Jul;101(1):66–72. doi: 10.1111/j.1365-2249.1995.tb02278.x

Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation.

R Segal 1, M Dayan 1, H Zinger 1, E Mozes 1
PMCID: PMC1553299  PMID: 7621594

Abstract

The objective of this study was to determine the effects of Methotrexate (MTX) on the development and the course of experimental murine SLE, as well as on the cytokine profile involved in the disease. SLE was induced in naive BALB/c female mice by injection of the human anti-DNA MoAb bearing a common idiotype (16/6 Id). Six weeks following immunization, when high levels of autoantibodies were demonstrated, the mice were treated with MTX (2 mg/kg once a week) for a period of 10 months. MTX treatment had no effect on 16/6 Id-induced autoantibody production. However, MTX treatment had beneficial effects on the clinical manifestations of the experimental disease (i.e. leucocyte counts, levels of protein in the urine and immune complex deposits in the kidneys). Thus, only 20% of 16/6 Id-immunized BALB/c mice that were treated with MTX had immune complex deposits in their kidneys compared with 100% of SLE-afflicted BALB/c mice that were not treated. We have observed a significant elevation in IL-1, tumour necrosis factor (TNF) and IL-10 secretion in BALB/c mice afflicted with experimental SLE. IL-2, IL-4, IL-6 and interferon-gamma (INF-gamma) levels were decreased in these mice compared with the levels detected in healthy controls. Treatment with MTX reversed the levels of all the above cytokines to normal levels observed in control mice. These studies demonstrate therapeutic effects of MTX on murine experimental SLE. The normal cytokine profile observed following treatment with MTX is suggested to play a role in the amelioration of the clinical manifestations of experimental SLE.

Full text

PDF
66

Images in this article

69Fig. 1
on p.69

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Abrams J. S., Roncarolo M. G., Yssel H., Andersson U., Gleich G. J., Silver J. E. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992 Jun;127:5–24. doi: 10.1111/j.1600-065x.1992.tb01406.x. [DOI] [PubMed] [Google Scholar]
  3. Abud-Mendoza C., Sturbaum A. K., Vazquez-Compean R., Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol. 1993 Apr;20(4):731–733. [PubMed] [Google Scholar]
  4. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990 Aug;4(11):2860–2867. [PubMed] [Google Scholar]
  5. Barrera P., Boerbooms A. M., Janssen E. M., Sauerwein R. W., Gallati H., Mulder J., de Boo T., Demacker P. N., van de Putte L. B., van der Meer J. W. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993 Aug;36(8):1070–1079. doi: 10.1002/art.1780360807. [DOI] [PubMed] [Google Scholar]
  6. Blank M., Ben-Bassat M., Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum. 1992 Nov;35(11):1350–1355. doi: 10.1002/art.1780351116. [DOI] [PubMed] [Google Scholar]
  7. Bridges A. J., Reid J. C., Cutts J. H., 3rd, Hazelwood S., Sharp G. C., Mitchell J. A. AI/LEARN/Rheumatology. A comparative study of computer-assisted instruction for rheumatology. Arthritis Rheum. 1993 May;36(5):577–580. doi: 10.1002/art.1780360501. [DOI] [PubMed] [Google Scholar]
  8. Conlon P. J. A rapid biologic assay for the detection of interleukin 1. J Immunol. 1983 Sep;131(3):1280–1282. [PubMed] [Google Scholar]
  9. Dinarello C. A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol. 1991 Dec;3(6):941–948. doi: 10.1016/s0952-7915(05)80018-4. [DOI] [PubMed] [Google Scholar]
  10. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991 Dec 1;147(11):3815–3822. [PubMed] [Google Scholar]
  11. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  12. Hu-Li J., Ohara J., Watson C., Tsang W., Paul W. E. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol. 1989 Feb 1;142(3):800–807. [PubMed] [Google Scholar]
  13. Kremer J. M. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol. 1994 Jan;21(1):1–5. [PubMed] [Google Scholar]
  14. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  15. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  16. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992 Apr;63(1):10–12. doi: 10.1016/0090-1229(92)90084-2. [DOI] [PubMed] [Google Scholar]
  17. Mendlovic S., Brocke S., Shoenfeld Y., Ben-Bassat M., Meshorer A., Bakimer R., Mozes E. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2260–2264. doi: 10.1073/pnas.85.7.2260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  19. Mosmann T. R., Schumacher J. H., Fiorentino D. F., Leverah J., Moore K. W., Bond M. W. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol. 1990 Nov 1;145(9):2938–2945. [PubMed] [Google Scholar]
  20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  21. Murakawa Y., Takada S., Ueda Y., Suzuki N., Hoshino T., Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol. 1985 Jan;134(1):187–195. [PubMed] [Google Scholar]
  22. O'Callaghan J. W., Bretscher P., Russell A. S. The effect of low dose chronic intermittent parental methotrexate on delayed type hypersensitivity and acute inflammation in a mouse model. J Rheumatol. 1986 Aug;13(4):710–714. [PubMed] [Google Scholar]
  23. Ramsey-Goldman R., Mientus J. M., Kutzer J. E., Mulvihill J. J., Medsger T. A., Jr Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol. 1993 Jul;20(7):1152–1157. [PubMed] [Google Scholar]
  24. Segal R., Mozes E., Yaron M., Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989 Apr;32(4):370–377. doi: 10.1002/anr.1780320403. [DOI] [PubMed] [Google Scholar]
  25. Segal R., Yaron M., Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum. 1990 Dec;20(3):190–200. doi: 10.1016/0049-0172(90)90060-s. [DOI] [PubMed] [Google Scholar]
  26. Segal R., Yaron M., Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum. 1990 Dec;20(3):190–200. doi: 10.1016/0049-0172(90)90060-s. [DOI] [PubMed] [Google Scholar]
  27. Segal R., Yaron M., Tartakovsky B. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum. 1990 Nov;33(11):1745–1748. doi: 10.1002/art.1780331121. [DOI] [PubMed] [Google Scholar]
  28. Singer D. S., Kohn L. D., Zinger H., Mozes E. Methimazole prevents induction of experimental systemic lupus erythematosus in mice. J Immunol. 1994 Jul 15;153(2):873–880. [PubMed] [Google Scholar]
  29. Singh A. K. Cytokines play a central role in the pathogenesis of systemic lupus erythematosus. Med Hypotheses. 1992 Dec;39(4):356–359. doi: 10.1016/0306-9877(92)90061-g. [DOI] [PubMed] [Google Scholar]
  30. Sthoeger Z. M., Bentwich Z., Zinger H., Mozes E. The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol. 1994 Dec;21(12):2231–2238. [PubMed] [Google Scholar]
  31. Tan P. L., Blumenstein M., Yeoman S., Watson J. D. B cell lymphokines in human systemic lupus erythematosus. Ann Rheum Dis. 1989 Nov;48(11):941–945. doi: 10.1136/ard.48.11.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269–390. doi: 10.1016/s0065-2776(08)60342-9. [DOI] [PubMed] [Google Scholar]
  33. Walz LeBlanc B. A., Dagenais P., Urowitz M. B., Gladman D. D. Methotrexate in systemic lupus erythematosus. J Rheumatol. 1994 May;21(5):836–838. [PubMed] [Google Scholar]
  34. Wilke W. S., Biro J. A., Segal A. M. Methotrexate in the treatment of arthritis and connective tissue diseases. Cleve Clin J Med. 1987 Jul-Aug;54(4):327–338. doi: 10.3949/ccjm.54.4.327. [DOI] [PubMed] [Google Scholar]
  35. Wilke W. S., Krall P. L., Scheetz R. J., Babiak T., Danao T., Mazanec D. J., Segal A. M., Clough J. D. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol. 1991 Nov-Dec;9(6):581–587. [PubMed] [Google Scholar]
  36. Willkens R. F., Watson M. A. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med. 1982 Sep;100(3):314–321. [PubMed] [Google Scholar]
  37. al-Janadi M., al-Balla S., al-Dalaan A., Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993 Jan;13(1):58–67. doi: 10.1007/BF00920636. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES